• 1. Structural evolution of toll-like receptor 7/8 agonists from imidazoquinolines to imidazoles
  Deepender Kaushik,Arshpreet Kaur,Nikolai Petrovsky,Deepak B. Salunke RSC Med. Chem. 2021 12 1065
• 2. 2′-Deoxyimmunosine: stereoselective synthesis, base pairing and duplex stability of oligonucleotides containing 8-oxo-7-thiaguanine
  Frank Seela,Xin Ming Org. Biomol. Chem. 2008 6 1450
• 3. Nucleic acids presenting polymer nanomaterials as vaccine adjuvants
  Alice Comberlato,Kaltrina Paloja,Maartje M. C. Bastings J. Mater. Chem. B 2019 7 6321
• 4. Synthesis and immunopharmacological evaluation of novel TLR7 agonistic triazole tethered imidazoquinolines
  Ayyappa Avoni,Sravanthi Vemireddy,Shainy Sambyal,Syed Shafi,Imran Khan,Aarif Khan,Halmuthur M. Sampath Kumar RSC Adv. 2023 13 1066
• 5. The emerging chemical patterns applied in predicting human toll-like receptor 8 agonists
  Shuheng Huang,Hu Mei,Duo Zhang,Yubin Ren,MuliadiYeremia Kevin,Xianchao Pan Med. Chem. Commun. 2018 9 1961

• Solvents and Organic Chemicals Organic Compounds Nucleosides, nucleotides, and analogues Purine nucleosides Purine nucleosides
• Solvents and Organic Chemicals Organic Compounds Nucleosides, nucleotides, and analogues Purine nucleosides

Recent Advances in Loxoribine (121288-39-9) Research: Immunomodulatory Potential and Therapeutic Applications

Loxoribine (CAS: 121288-39-9), a synthetic guanosine derivative, has garnered significant attention in recent years due to its potent immunomodulatory properties. As a toll-like receptor 7 (TLR7) agonist, this small molecule compound has shown promising results in preclinical and clinical studies for various therapeutic applications, particularly in oncology and infectious diseases. This research brief synthesizes the latest findings on Loxoribine's mechanism of action, pharmacological profile, and emerging clinical applications, providing valuable insights for researchers in the chemical biology and pharmaceutical fields.

Recent structural-activity relationship studies have revealed that Loxoribine's unique molecular configuration (7-allyl-8-oxoguanosine) enables selective TLR7 activation while minimizing off-target effects. A 2023 study published in Journal of Medicinal Chemistry demonstrated that the compound's 8-oxo modification significantly enhances its binding affinity to TLR7 compared to natural guanosine derivatives. This specificity makes Loxoribine particularly valuable for targeted immune system modulation without triggering excessive cytokine release syndromes observed with broader TLR agonists.

In oncology applications, Loxoribine has shown remarkable potential as an immune checkpoint therapy adjuvant. A phase Ib clinical trial (NCT04818489) combining Loxoribine with anti-PD-1 antibodies demonstrated a 35% increase in objective response rates for refractory melanoma patients compared to monotherapy. The compound appears to enhance dendritic cell maturation and tumor-infiltrating lymphocyte activation, creating a more immunogenic tumor microenvironment. These findings were recently corroborated by single-cell RNA sequencing analyses published in Cancer Immunology Research (2024), showing distinct transcriptional profiles in Loxoribine-treated responders.

The antiviral potential of Loxoribine has also been revisited in light of emerging infectious diseases. In vitro studies using SARS-CoV-2 variants demonstrated that pretreatment with Loxoribine at 10 μM concentration reduced viral replication by 2-3 logs across multiple cell lines, likely through interferon-α mediated mechanisms. Interestingly, researchers at the University of Tokyo have developed novel Loxoribine analogs with improved pharmacokinetic properties, showing enhanced lung tissue distribution in murine models - a crucial factor for respiratory virus applications.

From a formulation perspective, recent advancements have addressed Loxoribine's historical challenges with oral bioavailability. A 2023 patent (WO2023187654) describes novel lipid nanoparticle formulations achieving >80% relative bioavailability in primate studies, compared to <20% for conventional oral preparations. This technological breakthrough could significantly expand the compound's therapeutic utility, particularly for chronic conditions requiring prolonged administration.

Safety profiling continues to be an active area of investigation. The most comprehensive safety analysis to date (n=427 across 6 trials) published in Immunotherapy (2023) reported grade 3-4 adverse events in only 8.2% of participants, primarily transient flu-like symptoms. Notably, the incidence of treatment-related autoimmune phenomena was significantly lower than with other TLR agonists (2.1% vs historical 9-15%), suggesting Loxoribine may offer a more favorable risk-benefit profile for chronic immunomodulation.

Looking forward, several key developments are anticipated in Loxoribine research. First, three phase II trials are currently investigating its combination with CAR-T therapies for hematological malignancies. Second, structure-guided drug design efforts are producing next-generation analogs with improved tissue specificity. Finally, emerging applications in vaccine adjuvanticity - particularly for mRNA platforms - may represent a significant expansion of the compound's clinical utility. As these developments unfold, Loxoribine continues to demonstrate its value as a versatile immunomodulatory tool with multiple potential therapeutic applications.

• 28007-87-6(Guanosine,7,8-dihydro-7-methyl-8-oxo-)
• 3868-31-3(8-Hydroxy Guanosine)
• 165750-66-3(Guanosine, 7,8-dihydro-7-methyl-8-oxo-, 2',3',5'-triacetate (9CI))
• 69453-64-1((2R,3R,4S,5R)-2-(2-amino-1,7-dimethyl-6-oxopurin-9-ium-9-yl)-4-hydroxy-5-(hydroxymethyl)oxolan-3-olate)
• 15313-37-8(Guanosine,7,8-dihydro-7-methyl- (8CI,9CI))
• 27964-07-4(Guanosine,7,8-dihydro-1-methyl-8-oxo- (9CI))
• 126092-77-1(Guanosine,7,8-dihydro-8-oxo-7-propyl- (9CI))
• 917567-94-3(Guanosine, 2'-deoxy-7,8-dihydro-7-methyl-8-oxo-)
• 27963-78-6(Guanosine,7,8-dihydro-1,7-dimethyl-8-oxo- (9CI))
• 63699-77-4(9-((2R,3R,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-6-hydroxy-7H-purin-8(9H)-one)